ADvantage Therapeutics Inc.
ADvantage Therapeutics is dedicated to developing novel therapeutics for neurodegenerative conditions, with a major focus on Alzheimer’s Disease (AD). The company is currently approved for Phase 2 clinical trials in Europe and has an ILAP Passport designation from MHRA in the UK, which may allow for early commercialization after phase 2. With a research team at the Vienna BioCenter, ADvantage aims to create paradigm-changing therapies to treat AD and other aging-related diseases.
Industries
Nr. of Employees
small (1-50)
ADvantage Therapeutics Inc.
195 NW 40th Street, Miami, FL 33127
Patents
Products
Immunostimulant subcutaneous therapeutic candidate for early Alzheimer’s (clinical-stage)
A clinical-stage immunostimulant therapeutic candidate administered subcutaneously that demonstrated reduced hippocampal volume loss and slowed cognitive decline in a Phase 2 trial control arm; reported safety and tolerability in trial participants.
Immunostimulant subcutaneous therapeutic candidate for early Alzheimer’s (clinical-stage)
A clinical-stage immunostimulant therapeutic candidate administered subcutaneously that demonstrated reduced hippocampal volume loss and slowed cognitive decline in a Phase 2 trial control arm; reported safety and tolerability in trial participants.
Services
End-to-end clinical development for neurodegenerative disease candidates, including protocol execution, patient enrollment, biomarker collection, and outcome analysis for Phase 2 studies.
End-to-end clinical development for neurodegenerative disease candidates, including protocol execution, patient enrollment, biomarker collection, and outcome analysis for Phase 2 studies.
Expertise Areas
- Alzheimer’s disease therapeutics
- Clinical trial management (Phase 2)
- Immunology and immunotherapy development
- Biomarker-driven clinical research and neuroimaging
Key Technologies
- Mimotope-based vaccine and immunostimulant approaches
- Proteomics (clinical/translational)
- MRI-based volumetric imaging (hippocampal volumetry)
- Biomarker-enhanced clinical trial design
News & Updates
Klothea Bio collaborates with Healthy Longevity Clinic, a top semifinalist in the $101 million XPRIZE Healthspan competition.
Advantage Therapeutics Inc. announces the formation of Klothea Bio, Inc. to advance research and development of Klotho protein for age-related therapeutics.
ADvantage Therapeutics welcomes Dr. William Haseltine as a strategic advisor to drive innovation.
AD04T™ is a therapeutic approach for modifying Alzheimer’s disease through modulation of hippocampal lipid metabolism.
The company announced breakthrough findings showing that AD04™ has immediate symptomatic and disease-modifying properties in Alzheimer’s disease treatment.
Dr. Makoto Kuro-o, discoverer of the Klotho gene and pioneer in longevity and disease prevention, joins the scientific advisory board.
Klothea Bio collaborates with Healthy Longevity Clinic, a top semifinalist in the $101 million XPRIZE Healthspan competition.
Advantage Therapeutics Inc. announces the formation of Klothea Bio, Inc. to advance research and development of Klotho protein for age-related therapeutics.
ADvantage Therapeutics welcomes Dr. William Haseltine as a strategic advisor to drive innovation.
AD04T™ is a therapeutic approach for modifying Alzheimer’s disease through modulation of hippocampal lipid metabolism.
The company announced breakthrough findings showing that AD04™ has immediate symptomatic and disease-modifying properties in Alzheimer’s disease treatment.
Dr. Makoto Kuro-o, discoverer of the Klotho gene and pioneer in longevity and disease prevention, joins the scientific advisory board.